Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice

Ansell, Stephen M.; Ackerman, Michael J.; Black, John L.; Roberts, Lewis R.; Tefferi, Ayalew
March 2003
Mayo Clinic Proceedings;Mar2003, Vol. 78 Issue 3, p307
Academic Journal
Part VI. Highlights advances in DNA/RNA-based methods of susceptibility screening, disease diagnosis and prediction of treatment outcome in regard to both drug toxicity and response as applied to various areas of clinical medicine. Presymptomatic identification of high-risk patients; Understanding of the molecular basis of disease; Role of molecular genetics and genomics.


Related Articles

  • Medication safety tops list of pharmacy directors' concerns. Vecchione, Anthony // Drug Topics;7/26/2004, Vol. 148 Issue 14, HEALTH-SYSTEM EDITION p18 

    If you have any doubts about whether or not medication safety issues are keeping pharmacists up at night, you may want to take a look at the results of a survey conducted among pharmacy directors and taken at the 2004 meeting of the Pharmacy Leadership Institute. Health-system pharmacy directors...

  • Toxicidad hepática inducida por fármacos y herbolaria. de Fátima Higuera-de la Tijera, María; Servín-Caamaño, Alfredo Israel; Alexanderson-Rosas, Elvira Graciela // Revista Medica del Hospital General de Mexico;oct-dic2012, Vol. 75 Issue 4, p230 

    The liver is the principal responsible for nutrients, drugs and non-pharmacological substances metabolism. Drug-induced liver injury (DILI) is the most common cause associated with death by acute liver failure (ALF) and worldwide represents near of 10% of cases. DILI can be intrinsic or...

  • Therapeutic immunization for the control of HIV-1: where are we now? Dorrell, Lucy // International Journal of STD & AIDS;Jul2006, Vol. 17 Issue 7, p436 

    Highly active antiretroviral therapy (HAART) has transformed HIV-1 infection from an invariably fatal disease into a chronic infection requiring lifelong treatment. However, the challenges we still face are the urgent need to provide affordable sustainable therapy to the millions of infected...

  • RNAi and RNAa - The Yin and Yang of RNAome. Pushparaj, Peter Natesan; Aarthi, Jude J.; Kumar, Srinivasan D.; Manikandan, Jayapal // Bioinformation;2008, Vol. 2 Issue 6, p235 

    RNA interference (RNAi) is a powerful technology with huge applications for functional genomics, target identification in drug discovery and elucidation of molecular signaling pathways. Current RNAi studies have demonstrated the clinical potential of small interfering RNAs (siRNAs) in metabolic...

  • New Drug Delivery Systems Required.  // Pharmaceutical Technology Europe;May2005, Vol. 17 Issue 5, p10 

    The article reports that advances made in proteomics, genomics and biotechnology are breeding a new generation of therapeutics that require novel drug delivery systems for patients to receive maximum benefits. Numerous drug delivery companies have also become more proactive in participating in...

  • Clinical features and molecular genetics of hereditary peripheral neuropathies. Kuhlenbäumer, Gregor; Young, Peter; Hünermund, Gert; Ringelstein, Bernd; Stögbauer, Florian // Journal of Neurology;Dec2002, Vol. 249 Issue 12, p1629 

    Hereditary peripheral neuropathies are the most common monogenetically inherited diseases of the nervous system. The prevalence of the Hereditary Motor and Sensory Neuropathy Type 1A (HMSN 1A or Charcot-Marie-Tooth Neuropathy 1A, CMT1A) alone is estimated to be as high as 1/5000. In 1991, a...

  • Paracetamol poisoning: new guideline evaluated.  // PharmacoEconomics & Outcomes News;Apr2014, Vol. 700 Issue 1, p9 

    The article discusses research being done on the effect of the revised paracetamol poisoning management guidelines on admissions and costs of treatment, which references a study by D. N. Bateman et al published in the March 26, 2014 issue of the "British Journal of Clinical Pharmacology."

  • Changing a Failing Regimen.  // MMWR: Morbidity & Mortality Weekly Report;5/17/2002 Supplement RR-7, Vol. 51 Issue 19, p18 

    Discusses the considerations for changing antiretroviral therapy and available therapeutic options. Factors that are needed to be considered before changing regimens; Reason for the failure of a regimen; Difference between drug failure and drug toxicity.

  • Drugs and the QT Interval – Caveat Doctor. Liu, Barbara A.; Juurlink, David N. // New England Journal of Medicine;9/9/2004, Vol. 351 Issue 11, p1053 

    The authors discuss drugs have the potential to cause adverse effects. Occasionally, serious adverse effects are not identified in preclinical studies and become apparent only when a drug is in widespread clinical use. The discipline of pharmacoepidemiology has much to teach us about the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics